{
    "2019-04-09": [
        [
            {
                "time": "",
                "original_text": "泰格医药: Q1业绩超预期, 内生高增长",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "Q1",
                        "业绩",
                        "超预期",
                        "内生",
                        "高增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "泰格医药(300347)：国内创新药上市进口价值持续挖掘",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "300347",
                        "国内",
                        "创新药",
                        "上市",
                        "进口价值",
                        "持续挖掘"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【泰格医药】Q1预告点评：19Q1业绩超预期，股权激励高要求彰显信心",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "Q1",
                        "预告",
                        "点评",
                        "19Q1",
                        "业绩",
                        "超预期",
                        "股权激励",
                        "高要求",
                        "彰显信心"
                    ],
                    "sentiment_score": 0.92,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "泰格医药: 主营业务维持高速增长, 关注国际化进程",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "主营业务",
                        "维持",
                        "高速增长",
                        "关注",
                        "国际化",
                        "进程"
                    ],
                    "sentiment_score": 0.88,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}